After a four-month lapse, the US Food and Drug Administration announced plans to resume ‘prioritized’ domestic good manufacturing practice inspections on 20 July, focusing on states and localities that have low rates of COVID-19 infections.
In mid-March, the agency suspended all but the most “mission-critical” inspections due to the coronavirus pandemic. (Also see "US...





